UroAlert - GU Oncology Weekly

June 25, 2026

Videos

Peer-to-Peer Clinical Conversations

The MEVPRO-2 Phase 3 Trial of Mevrometostat plus Enzalutamide in ARPI-Naive mCRPC - Neal Shore

Neal Shore

Neal Shore describes the MEVPRO-2 trial design, a 900-patient double-blind randomized study of mevrometostat 875 mg twice daily with food plus enzalutamide versus enzalutamide alone in ARPI-naive mCRPC patients.

Evaluating Intermediate Surrogate Endpoints in Perioperative Bladder Cancer Trials - Pietro Scilipoti

Pietro Scilipoti

Pietro Scilipoti presents a surrogate endpoint analysis in perioperative muscle-invasive bladder cancer trials.

Beyond the Abstracts

Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use - Beyond the Abstract

Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer - Beyond the Abstract

Conference Coverage

ASCO 2026: Impact of FGFR3 Pathway Activation in Patients with MIBC Treated with Neoadjuvant Chemotherapy

ASCO 2026: Molecular Characterization of Residual Disease Post-Neoadjuvant Sacituzumab Govitecan, Pembrolizumab, or Their Combination in Patients with MIBC

AUA 2026: Development and Internal Validation of a Novel Prognostic Score for Real-world Renal Cell Carcinoma Patients Eligible for Adjuvant therapy

AUA 2026: ENLIGHTED Phase 3 Trial of Non-Thermal, Drug-Activated Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP) for Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC)

EAU 2026: Preliminary Results of a Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Combination with Radiotherapy for Adjuvant Therapy in Upper Tract Urothelial Carcinoma

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

A Pilot Study of Ex-vivo High Frequency Ultrasound and Core Needle Biopsy to Improve Clinical Tumor Staging of Cancer of the Bladder.

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.

CRISPR/Cas9-mediated miR-21 editing in high-grade urothelial carcinoma cells and its biological effects.

Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.

Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.

Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients.

Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy.

Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.

Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.

Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis.

Cystectomy Remains Standard of Care Following Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer.

Penile & Urethral Cancers

Front-line chemo-immunotherapy for advanced penile cancer: ready for prime time?

A focused systematic review and meta-analysis of robot-assisted inguinal lymphadenectomy versus open inguinal lymph node dissection in penile cancer.

Renal Cancer

Estimating the Sodium Content: A Case Series of Benign and Malignant Renal Tumours Using 23Na-MRI at 3 T.

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Co-design of a pre-surgical care intervention to support people undergoing prostatectomy for prostate cancer.

Real-World Comparison of the Effectiveness and Safety of Immune-Based Combinations in Elderly Patients with Advanced Renal Cell Carcinoma (ARON-1 Study) - Beyond the Abstract

Imaging modality, incidental detection, and age-stage distribution in surgically treated clear cell renal cell carcinoma.

Targeting RELA and STAT3 regulates TNFRSF10A-mediated apoptosis in a novel apoptosis-based prognostic model for clear cell renal cell carcinoma.

The Heterogeneity of B Cells Potentially Contributes to Metastasis of Clear Cell Renal Cell Carcinomas.

Preoperative MRI Model for Predicting Inferior Vena Cava Wall Invasion in Renal Cell Carcinoma with Tumor Thrombus.

Percutaneous Cryoablation for Small Renal Masses in a High-Risk Cohort: Oncologic and Functional Outcomes from a Five-Year Single-Center Experience.

Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment.

Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.

The evolution of kidney surgery for renal masses in Switzerland - a retrospective analysis.

1H MR-based detection of human plasma metabolic alterations in clear cell renal cell carcinoma.

Prostate Cancer

Criteria Clinicians Use to Classify Patients as High Risk in Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer.

A Practical Guide to PSMA PET Radiopharmaceuticals for Prostate Cancer Imaging, From the AJR Special Series on Molecular Imaging.

How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?

Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity.

Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.

Clinically Significant Prostate Cancer in Patients Undergoing Holmium Laser Enucleation of Prostate for Benign Hyperplasia: A Preoperative Nomogram and a Postoperative Surveillance Protocol.

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up.

Same Target, Different Tools: A Multicenter Comparison of Clinically Significant Prostate Cancer Detection Across Three MRI-Targeted Transperineal Biopsy Techniques

Current state of the art of new prostate MRI technologies and potential future developments.

Investigation of Potential Splenic Metastasis on Prostate-Specific Membrane Antigen (PSMA) Imaging in High-Risk Prostate Cancer: A Role for MRI?

Surgical Complications in a large series of Retzius-sparing robot-assisted radical prostatectomy: impact of surgical experience and technical modifications (1016 cases).

Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models.

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound.

Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.

Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre-Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors.

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

Prostate Cancer Working Group 4 Recap.

Association of asymptomatic PSA testing on prostate cancer mortality; a case control study in general practice.

Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation.

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Long-term Outcomes in Men with Stable PSA During 5-α Reductase Inhibitor Therapy After Negative Prostate Biopsy: Population-based Study.

Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.

AI-Assisted Prostate Cancer Diagnosis Using Biparametric MRI and PI-RADS v2.1: Performance Comparison Between Novice-Level and Experienced Readers.

Piggybacking Towards Progress for CAR-T Cell Therapy in Prostate Cancer.

The Landscape of Prostate Tumour Methylation.

Prostate Cancer Mortality Among Men with and Without Comorbidity: Long-Term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam - Beyond the Abstract

NeuroSAFE-Guided Robot-Assisted Radical Prostatectomy versus Standard RARP: Systematic Review and Meta-Analysis of Comparative Studies - Beyond the Abstract

Upper Tract Tumors

Nephroureterectomy with ileal cuff for upper tract recurrence after radical cystectomy: oncologic and survival outcomes.

Metachronous contralateral recurrence in upper tract urothelial carcinoma: a multi-institutional competing-risks analysis from the ROBUUST 3.0 registry.

Clinicopathological Predictors of Survival After Radical Nephroureterectomy for UTUC: A Propensity Score-Matched Multicenter Analysis.

Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance.

Pathologic Complete Response after Enfortumab Vedotin Plus Pembrolizumab in Node-positive Upper Tract Urothelial Carcinoma - Beyond the Abstract

Testicular Cancer

Impact of Treatment Intensity on Quality of Life in Patients With Metastatic Testicular Cancer.

Parental occupational exposure to pesticides at birth and risk of adult testicular germ cell tumours in offspring: a French nationwide case-control study.

Research trends and collaboration patterns in robotic retroperitoneal lymph node dissection for testicular cancer.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC